- ChemoCentryx (CCXI) is out with top-line data from a Phase 2 study of CCX168 in ANCA-associated AARV.
- In short, the company says the results demonstrate "that CCX168 appears to be safe, well tolerated and successful in allowing both reduction and elimination of high-dose corticosteroids, part of standard of care for AARV patients, without compromising efficacy or safety during a 12-week treatment period."
- The data (at 12 weeks): CCX168 plus CYC plus low-dose steroids, renal remission 75%, urinary MCP-1, -72%; CCX168 plus CYC plus no steroids, renal remission 63%, urinary MCP-1, -52%; SOC, renal remission 44%, urinary MCP-1, -37%. (PR)
- CCXI +6.5% AH
ChemoCentryx rallies on CCX168 data
Dec 3 2013, 16:34 ET